Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817799 | 0.79 | CA12 (0.38) | ERN1GAAPKMKDM4EGPR3 | |
| SCHEMBL4703998 | 0.76 | KDM4E (0.42) | ERN1KDM4EGPR3L3MBTL1HSD17B10 | |
| SCHEMBL830432 | 0.74 | ALDH3A1 (0.57) | GAAHTTALDH3A1POLBNOD1 | |
| SCHEMBL7102791 | 0.74 | TLR7 (0.54) | POLBLMNA | |
| SCHEMBL5092806 | 0.73 | KDM4E (0.42) | ERN1KDM4EGPR3HSD17B10HPGD | |
| SCHEMBL204996 | 0.73 | KDM4E (0.42) | ERN1GAAKDM4EGPR3TSHR | |
| SCHEMBL5528658 | 0.73 | KDM4E (0.42) | KDM4EGPR3HSD17B10HPGDGRM5 | |
| SCHEMBL5823463 | 0.73 | KDM4E (0.42) | ERN1GAAPKMKDM4EGPR3 | |
| SCHEMBL1486425 | 0.71 | KDM4E (0.41) | ERN1GAAPKMKDM4EGPR3 | |
| SCHEMBL4361065 | 0.71 | PDE4A (0.37) | ERN1GAAPKMHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642580-B1 | Sulfonamide substituted imidazoquinolines | COLEY PHARM GROUP INC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1638566-A4 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7199131-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1198233-B1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060106052-A1 | METHOD OF USING SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-18 | — | — | US | disclosed |
| US-7030131-B2 | Sulfonamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2006-04-18 | — | — | US | disclosed |
| EP-1642580-A1 | Sulfonamide substituted imidazoquinolines | 3M Innovative Properties Company (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638566-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-6924293-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040204438-A1 | Sulfonamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-6800624-B2 | INDUCE BIOSYNTHESIS OF CYTOKINES; IMMUNE RESPONSE MODIFIERS; TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-12 | — | — | US | disclosed |
| US-6677349-B1 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| EP-1198233-A4 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1198233-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6331539-B1 | INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-12-18 | — | — | US | disclosed |
| WO-2000076519-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | ERN1 1679/4885GAA 2938/4885PKM 3412/4885 |
| US-20060106052-A1 | METHOD OF USING SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | IFNG, MYD88, IL2 | ERN1 1737/4885GAA 2734/4885PKM 2615/4885 |
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | ERN1 1679/4885GAA 2938/4885PKM 3412/4885 |
| US-20040204438-A1 | Sulfonamide substituted imidazoquinolines | IRF3, IFNG, EIF2AK2 | ERN1 1056/4885GAA 3392/4885PKM 3242/4885 |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | ERN1 1679/4885GAA 2938/4885PKM 3412/4885 |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | ERN1 1679/4885GAA 2938/4885PKM 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.